The Bizarre Phenomena that Medicine Struggles to Explain | David Linden: Full Interview
Why It Matters
Understanding the brain’s direct control over hunger and reward opens up more effective, biologically grounded strategies for obesity and related disorders, while highlighting the therapeutic potential of mind‑body interventions.
Key Takeaways
- •Brain actively regulates hunger via rapid neural and hormonal signals.
- •GLP-1 drugs mimic natural gut hormones to suppress appetite long-term.
- •Artificial sweeteners create mismatched gut signals, undermining weight loss.
- •Mind-body interventions can modulate disease through autonomic and hormonal pathways.
- •GLP-1 therapies may affect broader reward behaviors beyond eating.
Summary
In this interview, Johns Hopkins neuroscientist David Linden explains how recent research is overturning the old split between mind and body, showing that the brain not only reacts to bodily states but actively governs them. He traces his own shift from skepticism to embracing neuroplasticity, emphasizing that mental practices—meditation, psychotherapy, controlled breathing—operate through concrete biological pathways rather than mystical forces. Linden details the two-way communication channels linking brain and body: fast electrical signals from intraceptive sensors, slower hormonal messengers, and the autonomic nervous system’s sympathetic‑parasympathetic balance. He uses the everyday act of choosing a pizza slice to illustrate how smell, memory, stomach stretch receptors, and intestinal GLP‑1 release converge to shape eating decisions. The discussion then turns to GLP‑1‑based drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound), which chemically modify the natural peptide to bind albumin, extending its half‑life and enabling once‑weekly injections that can produce 12‑17% body‑weight reductions. Linden highlights that artificial sweeteners fool oral sweet sensors but not gut receptors, creating conflicting signals that blunt satiety—a likely reason for their limited weight‑loss success. He also notes emerging evidence that GLP‑1 agonists may dampen other reward‑driven behaviors, from alcohol use to compulsive shopping, suggesting a broader impact on the brain’s reward circuitry. While the drugs are powerful, they carry side effects like nausea, gastrointestinal distress, and potential muscle loss, underscoring the need for concurrent exercise and protein intake. The implications are profound: clinicians can now view many chronic diseases—obesity, autoimmune disorders, even mental health conditions—as partly controllable through behavioral and pharmacological modulation of brain‑body loops. As the science of intraception and neuro‑immune signaling matures, new therapeutic avenues may emerge that combine lifestyle interventions with long‑acting hormonal agents, reshaping how we treat metabolic and psychiatric illnesses.
Comments
Want to join the conversation?
Loading comments...